Publikationen

2019

Ilhan H, Lindner S, Todica A, Cyran CC, Tiling R, Auernhammer CJ, Spitzweg C, Boeck S, Unterrainer M, Gildehaus FJ, Böning G, Jurkschat K, Wängler C, Wängler B, Schirrmacher R, Bartenstein P. Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019 Sep 6. doi: 10.1007/s00259-019-04501-6. [Epub ahead of print]
PMID: 31492994

Rudisile S, Gosewisch A, Wenter V, Unterrainer M, Böning G, Gildehaus FJ, Fendler WP, Auernhammer CJ, Spitzweg C, Bartenstein P, Todica A, Ilhan H. Salvage PRRT with 177Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival. BMC Cancer. 2019 Aug 8;19(1):788. doi: 10.1186/s12885-019-6000-y.
PMID: 31395036

Mintziras I, Keck T, Werner J, Fichtner-Feigl S, Wittel U, Senninger N, Vowinkel T, Köninger J, Anthuber M, Geißler B, Bartsch DK; StuDoQ|Pancreas Study Group of the German Society for General, Visceral Surgery (DGAV). Indications for resection and perioperative outcomes of surgery for pancreatic neuroendocrine neoplasms in Germany: an analysis of the prospective DGAV StuDoQ|Pancreas registry.  Surg Today. 2019 Jun 25. doi: 10.1007/s00595-019-01838-1. [Epub ahead of print]
PMID: 31240463

Bösch F, Bazhin AV, Heublein S, Brüwer K, Knösel T, Reiter FP, Auernhammer CJ, Guba MO, Spitzweg C, Werner J, Angele MK. Treatment with somatostatin analogs induces differentially expressed let-7c-5p and mir-3137 in small intestine neuroendocrine tumors. BMC Cancer. 2019 Jun 13;19(1):575. doi: 10.1186/s12885-019-5794-y.
PMID: 31196127

Jin XF, Auernhammer CJ, Ilhan H, Lindner S, Nölting S, Maurer J, Spoettl G, Orth M. Combination of 5-Fluorouracil With Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression and Radioligand Binding in Neuroendocrine Tumor Cells in Vitro.
J Nucl Med. 2019 Feb 22. pii: jnumed.118.224048. doi: 10.2967/jnumed.118.224048. [Epub ahead of print]
PMID: 30796167

Bösch F, Brüwer K, Altendorf-Hofmann A, Auernhammer CJ, Spitzweg C, Westphalen CB, Boeck S, Schubert-Fritschle G, Werner J, Heinemann V, Kirchner T, Angele M, Knösel T. Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia.
Endocr Relat Cancer. 2019 Mar 1;26(3):293-301. doi: 10.1530/ERC-18-0494.
PMID: 30608901

2018

Im Namen aller Teilnehmer/innen am Deutschen NET-Registers; Authors; Kollaboratoren:.[Neuroendocrine Neoplasia within the German NET Registry].
Z Gastroenterol. 2018 Oct;56(10):1237-1246. doi: 10.1055/a-0661-6099. Epub 2018 Oct 10. German.
PMID: 30304748

Kunz WG, Eschbach RS, Stahl R, Kazmierczak PM, Bartenstein P, Rominger A, Auernhammer CJ, Spitzweg C, Ricke J, Cyran CC. Identification and characterization of myocardial metastases in neuroendocrine tumor patients using 68Ga-DOTATATE PET-CT.
Cancer Imaging. 2018 Sep 20;18(1):34. doi: 10.1186/s40644-018-0168-2.
PMID: 30236163

Bösch F, Hofmann K, Coenen M, Pratschke S, Thomas M, Knösel T, Bruns CJ, Guba M, Werner J, Angele MK. Surgical treatment of pNET - Experience of a "high-volume" center. Surg Oncol. 2018 Sep;27(3):409-414. doi: 10.1016/j.suronc.2018.05.027. Epub 2018 May 29.
PMID: 30217295

Bösch F, Bruewer K, D'Anastasi M, Ilhan H, Knoesel T, Pratschke S, Thomas M, Rentsch M, Guba M, Werner J, Angele MK. Neuroendocrine tumors of the small intestine causing a desmoplastic reaction of the mesentery are a more aggressive cohort. Surgery. 2018 Jul 31. pii: S0039-6060(18)30370-2. doi: 10.1016/j.surg.2018.06.026. [Epub ahead of print]
PMID: 30076029

Aristizabal Prada ET, Spöttl G, Maurer J, Lauseker M, Koziolek EJ, Schrader J, Grossman A, Pacak K, Beuschlein F, Auernhammer CJ, Nölting S. The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance. Endocr Relat Cancer. 2018 Oct;25(10):893-908. doi: 10.1530/ERC-18-0159. Epub 2018 Jun 12.
PMID: 29895527

Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS); Netzwerk Neuroendokrine Tumoren (NeT) e.V. (Patientenvertretung); Bundesorganisation Selbsthilfe NeuroEndokrine Tumoren e.V. (NET-sgh) (Patientenvertretung); Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. (DGHO), und Arbeitsgemeinschaft Internistische Onkologie (AIO) der Deutschen Krebsgesellschaft e.V; Deutsche Gesellschaft für Allgemein- und Viszeralchirurgie e.V. (DGAV); Deutsche Gesellschaft für Chirurgie (DGCH); Deutsche Gesellschaft für Endoskopie und Bildgebende Verfahren (DGEBV); Deutsche Gesellschaft für Nuklearmedizin e.V. (DGNM); Deutsche Gesellschaft für Innere Medizin (DGIM); Deutsche Gesellschaft für Endokrinologie (DGE); Deutsche Gesellschaft für Palliativmedizin e.V. (DGP); Deutsche Röntgengesellschaft e.V. (DRG); Deutsche Gesellschaft für Pathologie e.V./Bundesverband Deutscher Pathologen (DGP/BDP); Deutsche Gesellschaft für interventionelle Radiologie (DGiR); Authors; Collaborators:.[Practice guideline neuroendocrine tumors - AWMF-Reg. 021-27]. Z Gastroenterol. 2018 Jun;56(6):583-681. doi: 10.1055/a-0604-2924. Epub 2018 Jun 11. German. PMID: 29890561

Aristizabal Prada ET, Heinzle V, Knösel T, Nölting S, Spöttl G, Maurer J, Spitzweg C, Angele M, Schmidt N, Beuschlein F, Stalla GK, Blaser R, Kuhn KA, Auernhammer CJ. Tropomyosin receptor kinase: a novel target in screened neuroendocrine tumors. Endocr Relat Cancer. 2018 May;25(5):547-560. doi: 10.1530/ERC-17-0201. Epub 2018 Mar 21. PMID: 29563190

Jin XF, Spampatti MP, Spitzweg C, Auernhammer CJ. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important. Rev Endocr Metab Disord. 2018 Feb 20. doi: 10.1007/s11154-018-9443-6. [Epub ahead of print] Review. PMID: 29464446

2017

Aristizabal Prada ET, Auernhammer CJ. Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets. Endocr Connect. 2018 Jan;7(1):R1-R25. doi: 10.1530/EC-17-0286. Epub 2017 Nov 16. Review. PMID: 29146887


Auernhammer CJ, Spitzweg C, Angele MK, Boeck S, Grossman A, Nölting S, Ilhan H, Knösel T, Mayerle J, Reincke M, Bartenstein P. Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies.
Lancet Diabetes Endocrinol. 2017 Dec 8. pii: S2213-8587(17)30401-1. doi: 10.1016/S2213-8587(17)30401-1. [Epub ahead of print] Review. PMID: 29229497


Aristizabal Prada ET, Weis C, Orth M, Lauseker M, Spoettl G, Maurer J, Grabowski P, Grossman A, Auernhammer CJ, Nölting S. GSK3α/β: A Novel Therapeutic Target for Neuroendocrine Tumors? Neuroendocrinology. 2017 Oct 2. doi: 10.1159/000481887. [Epub ahead of print]
PMID: 28968593


Nölting S, Rentsch J, Freitag H, Detjen K, Briest F, Möbs M, Weissmann V, Siegmund B, Auernhammer CJ, Aristizabal Prada ET, Lauseker M, Grossman A, Exner S, Fischer C, Grötzinger C, Schrader J, Grabowski P; GERMAN NET-Z study group. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models. PLoS One. 2017 Aug 11;12(8):e0182852. doi: 10.1371/journal.pone.0182852. eCollection 2017. PMID: 28800359

Aristizabal Prada, E. T., Nölting, S., Spoettl, G., Maurer, J., & Auernhammer, C. J. (2017a). The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro. Neuroendocrinology. http://doi.org/10.1159/000463386


Aristizabal Prada, E. T., Orth, M., Nölting, S., Spöttl, G., Maurer, J., & Auernhammer, C. (2017b). The MTH1 inhibitor TH588 demonstrates anti-tumoral effects alone and in combination with everolimus, 5-FU and gamma-irradiation in neuroendocrine tumor cells. PloS One, 12(5), e0178375. http://doi.org/10.1371/journal.pone.0178375


Paprottka KJ, Schoeppe F, Ingrisch M, Rübenthaler J, Sommer NN, De Toni E, Ilhan H, Zacherl M, Todica A, Paprottka PM. Pre-therapeutic factors for predicting survival after radioembolization: a single-center experience in 389 patients. Eur J Nucl Med Mol Imaging. 2017 Jul;44(7):1185-1193. doi: 10.1007/s00259-017-3646-z. Epub 2017 Feb 14.


Barrio M, Czernin J, Fanti S, Ambrosini V, Binse I, Du L, Eiber M, Herrmann K, Fendler WP. The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis.
J Nucl Med. 2017 May;58(5):756-761. doi: 10.2967/jnumed.116.185587. Epub 2017 Jan 12. Review.


Knösel T, Reiter C, Schubert-Fritschle G, Altendorf-Hofmann A, Kirchner T. [Neuroendocrine neoplasia of the stomach : What is new?]
Pathologe. 2017 Mar;38(2):98-104. doi: 10.1007/s00292-017-0269-x. German.

Werner RA, Lapa C, Ilhan H, Higuchi T, Buck AK, Lehner S, et al.: Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity. Oncotarget 2017 Jan 24;8:7039–7049.

Sabet, A., Haug, A. R., Eiden, C., Auernhammer, C. J., Simon, B., Bartenstein, P., et al. (2017). Efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis. American Journal of Nuclear Medicine and Molecular Imaging, 7(2), 74–83.

2016

Reuther C, Heinzle V, Nölting S, Herterich S, Hahner S, Halilovic E, et al.: The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53 - p21 - Rb - E2F1 Cascade in the p53wildtype Neuroendocrine Tumor Cell Line GOT1. Neuroendocrinology 2016 Nov 21; DOI: 10.1159/000453369

Werner RA, Lapa C, Ilhan H, Higuchi T, Buck AK, Lehner S, et al.: Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity. Oncotarget 2017 Jan 24;8:7039–7049.

Ilhan H, Wang H, Gildehaus FJ, Wängler C, Herrler T, Todica A, et al.: Nephroprotective effects of enalapril after [177Lu]-DOTATATE therapy using serial renal scintigraphies in a murine model of radiation-induced nephropathy. EJNMMI Res 2016 Dec;6:64.

Hörsch D, Ezziddin S, Haug A, Gratz KF, Dunkelmann S, Miederer M, et al.: Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up. Eur J Cancer 2016 May;58:41–51.

Kazmierczak PM, Rominger A, Wenter V, Spitzweg C, Auernhammer C, Angele MK, et al.: The added value of (68)Ga-DOTA-TATE-PET to contrast-enhanced CT for primary site detection in CUP of neuroendocrine origin. Eur Radiol 2016 Jul 19; DOI: 10.1007/s00330-016-4475-3

Wu Y, Tedesco L, Lucia K, Schlitter AM, Garcia JM, Esposito I, et al.: RSUME is implicated in tumorigenesis and metastasis of pancreatic neuroendocrine tumors. Oncotarget 2016 Aug 5; DOI: 10.18632/oncotarget.11081

Fielitz K, Althoff K, De Preter K, Nonnekens J, Ohli J, Elges S, Hartmann W, Klöppel G, Knösel T, Schulte M, Klein-Hitpass L, Beisser D, Reis H, Eyking A, Cario E, Schulte JH, Schramm A, Schüller U. Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells. Oncotarget. 2016 Nov 15;7(46):74415-74426. doi: 10.18632/oncotarget.12766.

2015

Nölting S, Maurer J, Spöttl G, Aristizabal Prada ET, Reuther C, Young K, Korbonits M, Göke B, Grossman A, Auernhammer CJ. Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways. PLoS One. 2015 Dec 4;10(12):e0143830. doi: 10.1371/journal.pone.0143830. eCollection 2015.

Reuther C, Heinzle V, Spampatti M, Vlotides G, de Toni E, Spöttl G, Maurer J, Nölting S, Göke B, Auernhammer CJ. Cabozantinib and Tivantinib, but not INC280, Induce Anti-Proliferative and Anti-Migratory Effects in Human Neuroendocrine Tumour Cells in vitro: Evidence for 'Off-Target' Effects not Mediated by c-Met Inhibition. Neuroendocrinology. 2015 Aug 25. [Epub ahead of print]

Ilhan H, Goritschan A, Paprottka P, Jakobs TF, Fendler WP, Todica A, Bartenstein P, Hacker M, Haug AR. Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors. J Nucl Med. 2015 Nov;56(11):1654-60. doi: 10.2967/jnumed.115.162685. Epub 2015 Aug 27.

Ilhan H, Fendler WP, Cyran CC, Spitzweg C, Auernhammer CJ, Gildehaus FJ, Bartenstein P, Angele MK, Haug AR. Impact of (68)Ga-DOTATATE PET/CT on the surgical management of primary neuroendocrine tumors of the pancreas or ileum. Ann Surg Oncol. 2015 Jan;22(1):164-71. doi: 10.1245/s10434-014-3981-2. Epub 2014 Sep 5.

Reuther C, Heinzle V, Spampatti M, et al. 2015 Cabozantinib and Tivantinib, but not INC280, Induce Anti-Proliferative and Anti-Migratory Effects in Human Neuroendocrine Tumour Cells in vitro: Evidence for ‘Off-Target’ Effects not Mediated by c-Met Inhibition. 2015;[PMID: 26338447 DOI: 10.1159/000439431]

2014

Friedrich M, Diegelmann J, Schauber J, Auernhammer CJ & Brand S 2014 Intestinal neuroendocrine cells and goblet cells are mediators of IL-17A-amplified epithelial IL-17C production in human inflammatory bowel disease. Mucosal Immunology. (doi:10.1038/mi.2014.124)
Vlotides G, Tanyeri A, Spampatti M, Zitzmann K, Chourdakis M, Spoettl G, Maurer J, Noelting S, Gke B & Auernhammer CJ 2014 Anticancer effects of metformin on neuroendocrine tumor cells in vitro. Hormones (Athens, Greece). (doi:10.14310/horm.2002.1517)
Anlauf M, Sipos B, Boeck I, Baldus SE, Heikaus S, Krausch M, Knoefel WT, Begum N, Goretzki P, Schott M et al. 2014 [Neuroendocrine neoplasms of the distal jejunum and ileum]. Der Pathologe 35 283–93–quiz294. (doi:10.1007/s00292-013-1888-5)

Ceelen F, Theisen D, de Albéniz XG, Auernhammer CJ, Haug AR, D'Anastasi M, Paprottka PM, Rist C, Reiser MF & Sommer WH 2014 Towards new response criteria in neuroendocrine tumors: Which changes in MRI parameters are associated with longer progression-free survival after radioembolization of liver metastases? Journal of Magnetic Resonance Imaging : JMRI. (doi:10.1002/jmri.24569)

Ilhan H, Fendler WP, Cyran CC, Spitzweg C, Auernhammer CJ, Gildehaus FJ, Bartenstein P, Angele MK & Haug AR 2014 Impact of (68)Ga-DOTATATE PET/CT on the Surgical Management of Primary Neuroendocrine Tumors of the Pancreas or Ileum. Annals of Surgical Oncology. (doi:10.1245/s10434-014-3981-2)

Koch W, Auernhammer CJ, Geisler J, Spitzweg C, Cyran CC, Ilhan H, Bartenstein P & Haug AR 2014 Treatment with octreotide in patients with well-differentiated neuroendocrine tumors of the ileum: prognostic stratification with Ga-68-DOTA-TATE positron emission tomography. Molecular Imaging 13 1–10.

Spampatti M, Vlotides G, Spöttl G, Maurer J, Göke B & Auernhammer CJ 2014 Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells. World Journal of Gastroenterology : WJG 20 10038–10049. (doi:10.3748/wjg.v20.i29.10038)

2013


Armbruster M, Zech CJ, Sourbron S, Ceelen F, Auernhammer CJ, Rist C, Haug A, Singnurkar A, Reiser MF & Sommer WH 2013 Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET/CT compared in patients with liver metastases from neuroendocrine neoplasms. Journal of Magnetic Resonance Imaging : JMRI. (doi:10.1002/jmri.24363)
Auernhammer C 2013 Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells. International Journal of Oncology. (doi:10.3892/ijo.2013.2130)
Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Beuschlein F, Wängler B, Uebleis C, Schmidt GP, Spitzweg C, Bartenstein P et al. 2013 "Neuroendocrine Tumor Recurrence: Diagnosis with 68Ga-DOTATATE PET/CT." Radiology. (doi:10.1148/radiol.13122501)
Armbruster M, Sourbron S, Zech CJ, Ingrisch M, Auernhammer CJ, Nikolaou K, Paprottka PM, Rist C, Reiser MF & Sommer WH 2013 "Evaluation of Neuroendocrine Liver Metastases: A Comparison of Dynamic Contrast-Enhanced Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography." Investigative Radiology. (doi:10.1097/RLI.0b013e3182a4eb4a)
Sommer WH, Ceelen F, García-Albéniz X, Paprottka PM, Auernhammer CJ, Armbruster M, Nikolaou K, Haug AR, Reiser MF, Theisen D. "Defining predictors for long progression-free survival after radioembolisation of hepatic metastases of neuroendocrine origin" Eur Radiol. 2013 Jun 28. [Epub ahead of print]
K Zitzmann, S Andersen, G Vlotides, G Spöttl, S Zhang, R Datta, M Culler, B Göke, and C J Auernhammer "The Novel SSTR2/D2R Chimeric Compound BIM-23A758 Decreases the Viability of Human GOT1 Midgut Carcinoid Cells." Neuroendocrinology. 2013 Jun 22. [Epub ahead of print]

2012

C. Schmid-Tannwald, C.M. Schmid-Tannwald, J.N. Morelli, R. Neumann, A.R. Haug, N. Jansen, K. Nikolaou, N. Schramm, M.F. Reiser, C. Rist, "Comparison of abdominal MRI with diffusion-weighted imaging to 68Ga-DOTATATE PET/CT in detection of neuroendocrine tumors of the pancreas." European Journal of Nuclear Medicine and Molecular Imaging 40 897–907.
S. Reu, J. Neumann, and T. Kirchner, “Gastrointestinal mixed adenoneuroendocrine carcinomas,” Pathologe, vol. 33, no. 1, pp. 31–38, Jan. 2012.
W. H. Sommer, C. J. Zech, F. Bamberg, C. J. Auernhammer, A. Helck, P. M. Paprottka, M. Notohamiprodjo, M. F. Reiser, and K. A. Herrmann, “Fluid-fluid level in hepatic metastases: a characteristic sign of metastases of neuroendocrine origin.,” Eur J Radiol, vol. 81, no. 9, pp. 2127–2132, Sep. 2012.
M. J. Willhauck, G. Pöpperl, W. Rachinger, A. Giese, C. J. Auernhammer, and C. Spitzweg, “An unusual case of ectopic ACTH syndrome.,” Exp Clin Endocrinol Diabetes, vol. 120, no. 2, pp. 63–67, Feb. 2012.
S. Sourbron, W. H. Sommer, M. F. Reiser, and C. J. Zech, “Combined quantification of liver perfusion and function with dynamic gadoxetic acid-enhanced MR imaging.,” Radiology, vol. 263, no. 3, pp. 874–883, Jun. 2012.
D. Hörsch, S. Ezziddin, A. Haug, K. F. Gratz, S. Dunkelmann, B. J. Krause, C. Schümichen, F. M. Bengel, W. H. Knapp, P. Bartenstein, H.-J. Biersack, U. Plöckinger, S. Schwartz-Fuchs, and R. P. Baum, “Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in Germany: First Results of a Multi-institutional Cancer Registry.,” Recent Results Cancer Res., vol. 194, pp. 457–465, 2012.
A. R. Haug, R. Cindea-Drimus, C. J. Auernhammer, M. Reincke, B. Wängler, C. Uebleis, G. P. Schmidt, B. Göke, P. Bartenstein, and M. Hacker, “The Role of 68Ga-DOTATATE PET/CT in Suspected Neuroendocrine Tumors.,” J Nucl Med, Sep. 2012.
N. Begum, S. Maasberg, U. Plöckinger, M. Anlauf, A. Rinke, G. Pöpperl, H. Lehnert, J. R. Izbicki, M. Krausch, Y. K. Vashist, A. Raffel, C. G. Bürk, J. Hoffmann, P. Goretzki, U. F. Pape, Weitere Vertreter des deutschen NET-Registers: Auernhammer C (Med. Klinik u. Poliklinik II, Klinikum der Ludwig-Maximilians Universität, Großhadern, München), Bartsch DK (Klinik f. Viszeral-, Thorax- u. Gefäßchirurgie, Universitätsklinikum Gießen u. Marburg, Marburg), Bechstein WO (Klinik f. Allgemein- u. Viszeralchirurgie, Universitätsklinikum der Johann Wolfgang Goethe Universität, Frankfurt am Main), Büchler MW (Chirurgische Universitätsklinik, Abt. f. Allgemein-, Viszeral- u. Transplantationschirurgie, Universitätsklinikum Heidelberg, Heidelberg), Daum S (Med. Klinik I, Gastroenterologie, Infektiologie, Rheumatologie, Charité – Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin), Fottner C (Med. Klinik u. Poliklinik I, Universitätsmedizin der Johannes Gutenberg-Universität, Mainz), Hörsch D (Klinik f. Innere Medizin, Gastroenterologie u. Endokrinologie, Zentralklinik Bad Berka GmbH, Bad Berka), Hoffmeister A (Gastroenterologie/Hepatologie u. Hämatologie/Onkologie, Universitätsklinikum Leipzig, Leipzig), Klose S (Klinik f. Nieren- und Hochdruckkrankheiten, Endokrinologie und Diabetologie, Universitätsklinikum Magdeburg A. ö. R., Magdeburg), Kudlich T (Med. Klinik u. Poliklinik II, Schwerpunkt Gastroenterologie, Endokrinologie, Universitätsklinikum Würzburg, Würzburg), Lahner H (Zentrum für Innere Medizin, Endokrinologie, Universitätsklinikum Essen, Essen), Lerch MM (Klinik f. Innere Medizin, Abt. f. Gastroenterologie u. Endokrinologie, Ernst-Moritz-Arndt Universitätsklinikum Greifswald, Greifswald), Mönig H (Klinik für Innere Medizin I, I. Med. Klinik, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel), Musholt T (Klinik u. Poliklinik f. Allgemein- u. Abdominalchirurgie, Universitätsmedizin der Johannes Gutenberg-Universität, Mainz), Nashan B (Klinik u. Poliklinik f. Chirurgie, Abt. f. Hepatobiliäre Chirurgie u. Transplantationszentrum, Universitätsklinikum Hamburg-Eppendorf, Hamburg), Niedergethmann M (Chirurgische Klinik, Universitätsklinikum Mannheim, Mannheim), Noe S (II. Med. Klinik u. Poliklinik, Gastroenterologie, Klinikum rechts der Isar der Technischen Universität München, München), Quitzsch D (Klinik f. Innere Medizin II, Gastroenterologie, Klinikum Chemnitz gGmbH, Chemnitz), Scheerer F (1. Med. Abteilung, Abteilung für Gastroenterologie, Hepatologie, Klinikum Neuperlach, München), Schepp W (2. Med. Abt. f. Gastroenterologie, Hepatologie u. gastroenterologische Onkologie, Klinikum Bogenhausen, München), Weber F (Klinik f. Allgemein-, Viszeral- u. Transplantationschirurgie, Universitätsklinikum Essen, Essen), Wurst C (Klinik für Allgemein-, Visceral- und Gefäßchirurgie, Klinikum der Fr. Schiller Universität Jena, Jena), “[Neuroendocrine Tumours of the GI Tract - Data from the German NET Registry.],” Zbl Chir, Oct. 2012.
K. Zitzmann, G.Vlotides, S. Brand, H. Lahm, G. Spoettl, B. Göke, and C. J. Auernhammer, Perifosine-mediated Akt inhibition in neuroendocrine tumor cells - role of specific Akt isoforms. Endocr Relat Cancer. 2012 10.1530/ERC-12-0074 1 [Epub ahead of print]
C.J. Auernhammer, C. Spitzweg, V. Heinemann, B. Göke, Medikamentöse Therapie bei metastasierten neuroendokrinen Tumoren des gastroenteropankreatischen Systems. Internist 2012  DOI 10.1007/s00108-011-2919-z1 [Epub ahead of print]
P.M. Paprotta, R.T. Hoffmann, A. Haug, W.H. Sommer, F. Raeßler, C.G. Trumm, G.P. Schmidt, N. Ashoori, M.F. Reiser, T.F. Jakobs, Radioembolization of Symptomatic, Unresectable Neuroendocrine Hepatic Metastases Using Yttrium-90 Microspheres.Cardiovasc Intervent Radiol 2012 Apr;35(2):334-42. Epub 2011 Aug 17.

2011

W.H. Sommer, C.J. Zech, F. Bamberg, C.J. Auernhammer, A. Helck, P.M. Paprottka, M. Notohamiprodjo , M.F. Reiser, K.A Herrmann, Fluid-fluid level in hepatic metastases: A characteristic sign of metastases of neuroendocrine origin.Eur J Radiol. 2011 Oct 4. [Epub ahead of print]
A.R. Haug, A. Rominger, M. Mustafa, C.J. Auernhammer, B. Göke, G.P. Schmidt, B. Wängler, P. Cumming, P. Bartenstein, M. Hacker, Treatment with Octreotide Does Not Reduce Tumor Uptake of 68Ga-DOTATATE as Measured by PET/CT in Patients with Neuroendocrine Tumors. J Nucl Med. November 1, 2011 vol. 52 no. 11 1679-1683
Zitzmann K, de Toni E, von Rüden J, Brand S, Göke B, Laubender RP, Auernhammer CJ., The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells. Endocr Relat Cancer. 2011 Mar 21;18(2):277-85.
R. T. Hoffmann, P. Paprottka, T. F. Jakobs, C. G. Trumm, and M. F. Reiser, “Arterial therapies of non-colorectal cancer metastases to the liver (from chemoembolization to radioembolization).,” Abdominal imaging, May. 2011.
W. H. Sommer, S. Sourbron, A. Huppertz, M. Ingrisch, M. F. Reiser, and C. J. Zech, “Contrast agents as a biological marker in magnetic resonance imaging of the liver: conventional and new approaches.,” Abdominal imaging, Apr. 2011.

2010

S. Nölting et al., “[Progressive dyspnoea in two patients with carcinoid syndrome.],” Der Internist, vol. 51, no. 11, pp. 1439–1445, Nov. 2010.
A. R. Haug et al., “68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors,” Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol. 51, no. 9, pp. 1349–1356, Sep. 2010.
C. Hantel et al., “Anti insulin-like growth factor I receptor immunoliposomes: a single formulation combining two anticancer treatments with enhanced therapeutic efficiency,” The Journal of clinical endocrinology and metabolism, vol. 95, no. 2, pp. 943–952, Feb. 2010.

2009

C. J. Auernhammer, K. W. Jauch, and J. N. Hoffmann, “[Liver metastases from neuroendocrine tumours of the gastroenteropancreatic system--therapeutic strategies],” Zentralblatt für Chirurgie, vol. 134, no. 5, pp. 410–417, Sep. 2009.
A. Haug et al., “Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours,” European journal of nuclear medicine and molecular imaging, vol. 36, no. 5, pp. 765–770, May. 2009.
M. P. Ebert et al., “[Gastrointestinal oncology - therapy update 2008 / 2009],” Zeitschrift für Gastroenterologie, vol. 47, no. 3, pp. 296–306, Mar. 2009.
C. Schmid-Tannwald, C. J. Zech, A. Panteleon, W. H. Sommer, C. Auernhammer, and K. A. Herrmann, “Characteristic imaging features of carcinoid tumors of the small bowel in MR enteroclysis,” Radiologe, vol. 49, no. 3, pp. 242–251, 2009.

2008

T. F. Jakobs, R. T. Hoffmann, K. Tatsch, C. Trumm, and M. F. Reiser, “[Therapy response of liver tumors after selective internal radiation therapy].,” Der Radiologe, vol. 48, no. 9, pp. 839–849, Sep. 2008.

2007

K. Zitzmann et al., “SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells,” Cancer research, vol. 67, no. 10, pp. 5025–5032, May. 2007.
C. J. Auernhammer and B. Göke, “Medical treatment of gastrinomas,” Wiener klinische Wochenschrift, vol. 119, no. 19, pp. 609–615, 2007.

2006

K. Zitzmann et al., “Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells,” Biochemical and biophysical research communications, vol. 344, no. 4, pp. 1334–1341, Jun. 2006.